“Generalized Pustular Psoriasis (GPP) Control Is Limited on Traditional Small-Molecule Therapy As Measured by the GPP Physician Global Assessment (GPPGA) and Dermatology Life Quality Index (DLQI): Baseline Data from the EFFISAYIL® 2 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 2, Mar. 2025, p. s540, https://doi.org/10.25251/skin.10.supp.540.